AndreaBozzo/ceres-open-data-index huggingface dataset:
Youth Risk Behavioral Surveillance System (YRBSS) - Mental Health Indicators

Data source description: YRBSS measures health-related behaviors and experiences that can lead to death and disability among youth and adults. Results help monitor health trends, identify emerging issues, and plan and evaluate programs that can help improve adolescent health. Responses from adolescents were used to produce estimates of experiences, behaviors, and conditions related to mental health and well-being for the nation and participating states. For additional information, please see: [Mental Health Data Sources].
Weekly United States COVID-19 Cases and Deaths among Dialysis Patients - ARCHIVED

Mandated reporting of Weekly Aggregate Case and Death Count data among dialysis patients and dialysis facility staff (healthcare personnel or HCP) in the United States was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will contain weekly aggregate data from January 1, 2021, through May 10, 2023, and will remain publicly available. This archived public use dataset contains reported COVID-19 case and death data per week for all states and territories, along with weekly totals for the entire United States, throughout the given timeframe.
Weekly Respiratory Virus Vaccination Data, Children 6 Months-17 Years and Adults 18 Years and Older, National Immunization Survey

*Vaccination data updates for the 2024-2025 respiratory illness season ended on May 2, 2025. The weekly respiratory virus vaccination data come from the National Immunization Survey-Adult COVID Module (NIS-ACM), National Immunization Survey-Child COVID Module (NIS-CCM), and the National Immunization Survey-Flu (NIS-Flu). The NIS-ACM provides data on Influenza (flu), COVID-19, and RSV vaccination for adults aged ≥18 years in the United States. The NIS-CCM provides data on COVID-19 vaccination for children aged 6 months-17 years in the United States. The NIS-Flu provides data on Influenza vaccination for children aged 6 months-17 years in the United States National Immunization Survey data are collected by telephone interview using a random-digit-dialed sample of cellular telephone numbers stratified by state, the District of Columbia, five local jurisdictions (Bexar County TX, Chicago IL, Houston TX, New York City NY, and Philadelphia County PA), and Guam, Puerto Rico, and the United States Virgin Islands. Data are weighted to represent the non-institutionalized United States population and mitigate possible bias that can result from incomplete sample frame (exclusion of households with no phone service or only landline telephones) or non-response. All responses are self-reported, or reported by a parent for children 6 months-17 years. For more information about the surveys, see https://www.cdc.gov/vaccines/imz-managers/nis/about.html#current-surveys. Estimates should be interpreted with caution when there is a small sample size or wide confidence interval.
Weekly Provisional Counts of Deaths by State and Select Causes, 2020-2023

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. Provisional counts of deaths by the week the deaths occurred, by state of occurrence, and by select underlying causes of death for 2020-2023. The dataset also includes weekly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death. NOTE: death counts are presented with a one week lag.
Weekly Percent of Pregnant Women Ages 18-49 Years Vaccinated with Respiratory Syncytial Virus (RSV) Vaccine Overall and by Race and Ethnicity

Weekly RSV Vaccination Coverage, Pregnant Women 18-49 Years Old by Race and Ethnicity Weekly RSV vaccination coverage estimates for pregnant women 18–49 years are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC's Immunization Safety Office and multiple integrated health care organizations.* The denominator includes those who reached at least 32 weeks' gestation since September 1, 2025. The numerator includes those who have received an RSV vaccine during pregnancy as of the week ending date. Pregnant women are not removed from the numerator or denominator when the pregnancy ends. Cumulative vaccination coverage for one week may be lower than cumulative coverage for a previous week due to the addition of pregnant women in the denominator. Additionally, no requirements for length of enrollment in a VSD site are applied, and vaccinations given outside of a VSD site might not be included.
Weekly Parental Intent for Vaccination and Cumulative Percentage of Children 6 Months-17 Years who are up to date with the updated 2023-24 COVID-19 Vaccine

• COVID-19 vaccination coverage and parental intent among children 6 months to 17 years is assessed through the National Immunization Survey providing weekly COVID-19 vaccination coverage estimates (https://www.cdc.gov/vaccines/imz-managers/nis/about.html). • Weekly estimates of COVID-19 vaccination coverage and parental intent for vaccination among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim). • Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.
Weekly Parental Intent for Vaccination and Cumulative Percentage of Children 6 Months -17 Years Who are Up to date with the COVID-19 Vaccines by Season, United States

• Weekly Parental Intent for Vaccination and Cumulative Percentage of Children 6 Months-17 Years Who are Up to date with the COVID-19 Vaccines by Season. • Weekly estimates of COVID-19 vaccination coverage and parental intent for vaccination among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM). (https://www.cdc.gov/nis/about/index.html). The NIS-CCM was discontinued at the end of 2023 and questions regarding COVID-19 vaccination status and intent were added to the National Immunization Survey-Flu (NIS-Flu) (https://www.cdc.gov/nis/about/index.html). • NIS-CCM and NIS-Flu are national random-digit dial cellular telephone surveys of households with children ages 6 months through 17 years; NIS-Flu is conducted during October-June. The respondent to a NIS-Flu survey is a parent or guardian who said they were knowledgeable about the child’s vaccination history. All estimates are based upon parental report of receipt of vaccination and month of that vaccination. • Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 and 2025–26 COVID-19 vaccines were first available at the end of August 2024 and 2025, respectively. • The NIS-Flu data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel (https://www.cdc.gov/respiratory-viruses/data/index.html). This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Influenza Vaccination Status and Intent for Vaccination, Overall, by Selected Demographics, and Jurisdiction, Children 6 Months-17 Years, United States

• Weekly Influenza Vaccination Status and Intent for Vaccination, Overall, by Selected Demographics, and Jurisdiction, Children 6 Months-17 Years. • Weekly Influenza vaccination coverage and parental intent for vaccination among children is calculated using data from the National Immunization Survey–Flu (NIS–Flu) (https://www.cdc.gov/nis/about/index.html). NIS–Flu is a national random-digit-dialed cellular telephone survey of households with children ages 6 months–17 years conducted during October-June. The respondent to a NIS–Flu survey is a parent or guardian who said they were knowledgeable about the child’s vaccination history. All estimates are based upon parental report of receipt of vaccination and month of that vaccination. • The NIS-Flu data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel (https://www.cdc.gov/respiratory-viruses/data/index.html). This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Influenza Vaccination Coverage and Intent for Vaccination, Overall, by Selected Demographics and Jurisdiction, Among Adults 18 Years and Older

• Weekly Influenza Vaccination Coverage and intent among adults 18 Years and Older by Demographic Characteristics and Jurisdiction • Weekly estimates of influenza vaccination coverage and intent for vaccination among adults are calculated using data from the National Immunization Surveys (NIS)-Fall Respiratory Virus Module (NIS-FRVM) (https://www.cdc.gov/nis/about/index.html). The NIS-FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon self-reported receipt of vaccination and month of that vaccination. • The NIS-FRVM data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel (https://www.cdc.gov/respiratory-viruses/data/index.html). This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Differences in Cumulative RSV Vaccination Coverage Among Adults 75 and Older and 60–74 Years with High-Risk Conditions Ever Vaccinated with RSV Vaccine, Overall, by Selected Demographics

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction • Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/) • In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.
Weekly Differences in Cumulative RSV Vaccination Coverage Among Adults 75 and Older and 60-74 Years with High-Risk Conditions Ever Vaccinated with RSV Vaccine, Overall, by Selected Demographics

. Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60?74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction . Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60?74 years with high risk conditions are calculated using data from the National Immunization Survey-Adult COVID Module (NIS-ACM) (https://www.cdc.gov/nis/about/) . In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ?60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60-74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.?
Weekly Differences in Cumulative Respiratory Syncytial Virus (RSV) Vaccination Coverage and Comparison, Overall, by Jurisdiction, Among Adults 75 Years and Older and Adults 50-74 Years with High-Risk Conditions

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 50-74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction • Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 50-74 years with high risk conditions are calculated using data from the National Immunization Survey - Fall Respiratory Virus Module (NIS–FRVM). The NIS-FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. • In June 2025, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged 50–74 years who are at increased risk for severe RSV disease may receive a single dose of an RSV vaccine. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older. The data below capture ever receiving a dose of an RSV vaccine by adults 50 years and older. • The NIS-FRVM data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel. This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Influenza Vaccination Status and Intent for Vaccination, Overall, by Selected Demographics, and Jurisdiction, Children 6 Months - 17 Years, 2023-24, United States

• Influenza vaccination coverage and parental intent among children 6 months to 17 years is assessed through the National Immunization Survey-Child COVID Module providing weekly COVID-19 vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html) • For the 2023-2024 flu season, the CDC recommends a flu shot for most people 6 months and older.
Weekly Differences in Cumulative Percentage of Children Ages 6 Months -17 Years who are up to date with the updated 2023-24 COVID-19 Vaccine, by Selected Demographics

• Weekly COVID-19 vaccination coverage estimates among children 6 months to 17 years is assessed through the National Immunization Survey (https://www.cdc.gov/vaccines/imz-managers/nis/about.html). • Weekly estimates of COVID-19 vaccination coverage among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM) (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-ccm). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim). • Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.
Weekly Differences in Cumulative Influenza Vaccination Coverage by Selected Demographics and by Season, 2025– 26 and 2025–26 Compared with 2024–25, Children 6 Months–17 Years, United States

• Weekly Differences in Cumulative Influenza Vaccination Coverage by Selected Demographics and by Season, 2025–26 and 2025–26 Compared with 2024–25, Children 6 Months–17 Years, United States. • Weekly Influenza vaccination coverage and parental intent for vaccination among children is calculated using data from the National Immunization Survey–Flu (NIS–Flu) (https://www.cdc.gov/nis/about/index.html). NIS–Flu is a national random-digit-dialed cellular telephone survey of households with children ages 6 months–17 years conducted during October-June. The respondent to a NIS–Flu survey is a parent or guardian who said they were knowledgeable about the child’s vaccination history. All estimates are based upon parental report of receipt of vaccination and month of that vaccination. • The NIS-Flu data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel (https://www.cdc.gov/respiratory-viruses/data/index.html). This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Differences in Cumulative Influenza Vaccination Coverage by Selected Demographics and by Season 2025–26 and 2025–26 Compared with 2024–25 Among Adults 18 Years, Overall, by Selected Demographics

• Weekly Influenza Vaccination Coverage and Comparison among adults 18 Years and Older by Jurisdiction. • Weekly estimates of influenza vaccination coverage and intent for vaccination among adults are calculated using data from the National Immunization Surveys (NIS)-Fall Respiratory Virus Module (NIS-FRVM). The NIS-FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon self-reported receipt of vaccination and month of that vaccination. • The NIS-FRVM data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel. This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Differences in Cumulative COVID-19 Vaccination Coverage by Selected Demographics and by Season, Among Adults 18 Years, Overall

• Weekly COVID-19 Vaccination Coverage and Comparison among adults 18 Years and Older by Selected Demographics and by Season • Weekly estimates of COVID-19 vaccination coverage and intent for vaccination among adults are calculated using data from the National Immunization Surveys (NIS)-Fall Respiratory Virus Module (NIS-FRVM) (https://www.cdc.gov/nis/about/index.html). • The NIS–FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon self-reported receipt of vaccination and month of that vaccination. • Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 and 2025–26 COVID-19 vaccines were first available at the end of August 2024 and 2025, respectively. • The NIS-FRVM data posted on the dashboard below are currently a few days behind the data that are posted on the Respiratory Illnesses Data Channel (https://www.cdc.gov/respiratory-viruses/data/index.html). This lag is due to the time it takes to review data by geographic and sociodemographic characteristics and summarize the findings.
Weekly Cumulative Updated 2023-24 COVID-19 Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years, United States, Data Source: Centers for Medicare & Medicaid Services Chronic Conditions Warehouse

Weekly Cumulative Updated 2023-24 COVID-19 Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years • Estimated COVID-19 vaccination coverage among Medicare fee-for-service beneficiaries >65 years is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS). • Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19. (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)
Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥75 years and enrolled in a Part D plan, United States, Data Source: Centers for Medicare & Medicaid Services Chronic Conditions Warehouse

• Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged 75 years • RSV vaccination coverage among Medicare-Fee-for-service beneficiaries aged 75 years and older and enrolled in a Part D plan in assessed using data files from the Medicare Fee-for-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS).
Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥75 years and Enrolled in a Part D plan, United States, Data Source: Centers for Medicare & Medicaid Services Chronic Conditions Warehouse

• RSV vaccination coverage among Medicare fee-for-service beneficiaries aged 75 years and older enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS). • Weekly RSV vaccination coverage estimates were calculated using Kaplan-Meier survival analysis, based on beneficiaries enrolled as of August 1, 2023. RSV vaccines received since August 1, 2023, among adults who were 75 years or older as of the end of the first year of the season (e.g., December 31, 2025, for the 2025–26 season), were included.
Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years, United States, Data Source: Centers for Medicare & Medicaid Services Chronic Conditions Warehouse

Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged 65 years • Estimated COVID-19 vaccination coverage among Medicare fee-for-service beneficiaries >65 years is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS). • Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html
Weekly Cumulative RSV Vaccination Coverage and Intent, Overall, by Selected Demographics and Jurisdiction, Among Adults 75 and Older and 60-74 Years with High-Risk Conditions Ever Vaccinated, United States

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction • Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/index.html). • In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.